259 related articles for article (PubMed ID: 17080304)
1. Glucosylceramide transfer from lysosomes--the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data.
Elleder M
J Inherit Metab Dis; 2006 Dec; 29(6):707-15. PubMed ID: 17080304
[TBL] [Abstract][Full Text] [Related]
2. Glucosylceramide and glucosylsphingosine metabolism in cultured fibroblasts deficient in acid beta-glucosidase activity.
Sasagasako N; Kobayashi T; Yamaguchi Y; Shinnoh N; Goto I
J Biochem; 1994 Jan; 115(1):113-9. PubMed ID: 8188616
[TBL] [Abstract][Full Text] [Related]
3. Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable In Vivo Preclinical Studies of Neuronopathic Gaucher Disease.
Hamler R; Brignol N; Clark SW; Morrison S; Dungan LB; Chang HH; Khanna R; Frascella M; Valenzano KJ; Benjamin ER; Boyd RE
Anal Chem; 2017 Aug; 89(16):8288-8295. PubMed ID: 28686011
[TBL] [Abstract][Full Text] [Related]
4. Role of β-glucosidase 2 in aberrant glycosphingolipid metabolism: model of glucocerebrosidase deficiency in zebrafish.
Lelieveld LT; Mirzaian M; Kuo CL; Artola M; Ferraz MJ; Peter REA; Akiyama H; Greimel P; van den Berg RJBHN; Overkleeft HS; Boot RG; Meijer AH; Aerts JMFG
J Lipid Res; 2019 Nov; 60(11):1851-1867. PubMed ID: 31562193
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.
Barnes S; Xu YH; Zhang W; Liou B; Setchell KD; Bao L; Grabowski GA; Sun Y
PLoS One; 2014; 9(12):e116023. PubMed ID: 25551612
[TBL] [Abstract][Full Text] [Related]
6. Gaucher disease: pathological mechanisms and modern management.
Jmoudiak M; Futerman AH
Br J Haematol; 2005 Apr; 129(2):178-88. PubMed ID: 15813845
[TBL] [Abstract][Full Text] [Related]
7. Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard.
Mirzaian M; Wisse P; Ferraz MJ; Gold H; Donker-Koopman WE; Verhoek M; Overkleeft HS; Boot RG; Kramer G; Dekker N; Aerts JM
Blood Cells Mol Dis; 2015 Apr; 54(4):307-14. PubMed ID: 25842368
[TBL] [Abstract][Full Text] [Related]
8. GCase and LIMP2 Abnormalities in the Liver of Niemann Pick Type C Mice.
van der Lienden MJC; Aten J; Marques ARA; Waas ISE; Larsen PWB; Claessen N; van der Wel NN; Ottenhoff R; van Eijk M; Aerts JMFG
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33802460
[TBL] [Abstract][Full Text] [Related]
9. Consequences of excessive glucosylsphingosine in glucocerebrosidase-deficient zebrafish.
Lelieveld LT; Gerhardt S; Maas S; Zwiers KC; de Wit C; Beijk EH; Ferraz MJ; Artola M; Meijer AH; Tudorache C; Salvatori D; Boot RG; Aerts JMFG
J Lipid Res; 2022 May; 63(5):100199. PubMed ID: 35315333
[TBL] [Abstract][Full Text] [Related]
10. Lipids regulate the hydrolysis of membrane bound glucosylceramide by lysosomal β-glucocerebrosidase.
Abdul-Hammed M; Breiden B; Schwarzmann G; Sandhoff K
J Lipid Res; 2017 Mar; 58(3):563-577. PubMed ID: 28126847
[TBL] [Abstract][Full Text] [Related]
11. Glucosylceramide modulates endolysosomal pH in Gaucher disease.
Sillence DJ
Mol Genet Metab; 2013 Jun; 109(2):194-200. PubMed ID: 23628459
[TBL] [Abstract][Full Text] [Related]
12. Neuronal activity induces glucosylceramide that is secreted via exosomes for lysosomal degradation in glia.
Wang L; Lin G; Zuo Z; Li Y; Byeon SK; Pandey A; Bellen HJ
Sci Adv; 2022 Jul; 8(28):eabn3326. PubMed ID: 35857503
[TBL] [Abstract][Full Text] [Related]
13. Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons.
Korkotian E; Schwarz A; Pelled D; Schwarzmann G; Segal M; Futerman AH
J Biol Chem; 1999 Jul; 274(31):21673-8. PubMed ID: 10419477
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide.
Bodennec J; Pelled D; Riebeling C; Trajkovic S; Futerman AH
FASEB J; 2002 Nov; 16(13):1814-6. PubMed ID: 12223447
[TBL] [Abstract][Full Text] [Related]
15. In vitro accumulation of glucocerebroside in neuroblastoma cells: a model for study of Gaucher disease pathobiology.
Prence EM; Chaturvedi P; Newburg DS
J Neurosci Res; 1996 Feb; 43(3):365-71. PubMed ID: 8714525
[TBL] [Abstract][Full Text] [Related]
16. Altered lysosome distribution is an early neuropathological event in neurological forms of Gaucher disease.
Zigdon H; Meshcheriakova A; Farfel-Becker T; Volpert G; Sabanay H; Futerman AH
FEBS Lett; 2017 Mar; 591(5):774-783. PubMed ID: 28186340
[TBL] [Abstract][Full Text] [Related]
17. Analysis of glucocerebrosidase activity using N-(1-[14C]hexanoyl)-D-erythroglucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease.
Meivar-Levy I; Horowitz M; Futerman AH
Biochem J; 1994 Oct; 303 ( Pt 2)(Pt 2):377-82. PubMed ID: 7980395
[TBL] [Abstract][Full Text] [Related]
18. The
Dai GY; Yin J; Li KE; Chen DK; Liu Z; Bi FC; Rong C; Yao N
J Biol Chem; 2020 Jan; 295(3):717-728. PubMed ID: 31819005
[TBL] [Abstract][Full Text] [Related]
19. The synthetic pathway for glucosylsphingosine in cultured fibroblasts.
Yamaguchi Y; Sasagasako N; Goto I; Kobayashi T
J Biochem; 1994 Sep; 116(3):704-10. PubMed ID: 7852294
[TBL] [Abstract][Full Text] [Related]
20. Direct activation of microglia by β-glucosylceramide causes phagocytosis of neurons that exacerbates Gaucher disease.
Shimizu T; Schutt CR; Izumi Y; Tomiyasu N; Omahdi Z; Kano K; Takamatsu H; Aoki J; Bamba T; Kumanogoh A; Takao M; Yamasaki S
Immunity; 2023 Feb; 56(2):307-319.e8. PubMed ID: 36736320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
